Related Experiment Video

Updated: Jun 27, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Availability of genome-matched therapy based on clinical practice

Naomi Hayashi1,2, Seiichi Mori3, Akihiro Ohmoto4,5

  • 1Department of Genomic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto, Tokyo, 135-8550, Japan. naomi.hayashi@jfcr.or.jp.

International Journal of Clinical Oncology
|April 26, 2024
PubMed
Abstract

Insights

Comprehensive genomic profiling (CGP) shows promise for advanced cancer patients, particularly for sarcoma and head and neck cancers. Early CGP may increase access to genome-matched therapies despite existing barriers.

Area of Science:

  • Oncology
  • Genomics
  • Precision Medicine

Background:

  • Comprehensive genomic profiling (CGP) offers potential for genome-matched therapies in advanced cancer.
  • Current availability rates for these targeted therapies remain low.
  • This study examines CGP utility and access barriers from a clinical viewpoint.

Purpose of the Study:

  • To assess the utility of CGP in identifying druggable genomic alterations across various cancer types.
  • To investigate barriers hindering patient access to genome-matched therapies.
  • To propose strategies for improving therapy availability.

Main Methods:

  • Retrospective analysis of 653 patients with 30 cancer types who underwent CGP.
  • Identification of druggable genomic alterations and assessment of genome-matched therapy availability.
  • Evaluation of barriers to accessing targeted therapies, including performance status.

Main Results:

  • Overall genome-matched therapy availability was 9.5%.
  • High rates of druggable alterations were found in thyroid (100%) and lung (76%) cancers; sarcoma had 15.2%.
  • Therapy availability was highest for sarcoma (60%) and head and neck cancer (HNC) (40%).
  • Multiple barriers affected 63.5% of patients; 11.8% were excluded due to poor performance status.

Conclusions:

  • CGP is clinically useful for sarcoma and HNC, in addition to lung cancer.
  • Front-line CGP has the potential to enhance genome-matched therapy accessibility.
  • Addressing barriers is crucial for realizing the full benefit of precision oncology.
Keywords:
Comprehensive genomic profilingGenome-matched therapy availabilityPractical strategy

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

498
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.5K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
326
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520